Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS)

Fig. 5

Serum Lcn2 levels after rosiglitazone (Rosi) or bisphenol A diglycidyl ether (BADGE) treatments in mice. A. Study design. B. Serum Lcn2 levels of ank/ank mice before and after Rosi/BADGE treatments. C. Serum Lcn2 levels of C3FeB6-A/Aw-jwt/wt mice before and after Rosi/BADGE treatments. UN: untreated animals (baseline); DM: 5% DMSO control animals; Rosi: 10 mg/kg body weight rosiglitazone treated animals; BAD: 30 mg/kg body weight bisphenol A diglycidyl ether (BADGE) treated animals. One-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test was used

Back to article page